Hepatitis C Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

 Market Overview:

The hepatitis C market reached a value of USD 19.7 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 51.4 Billion by 2035, exhibiting a growth rate (CAGR) of 8.77% during 2025-2035.

The hepatitis C market has been comprehensively analyzed in IMARC's new report titled "Hepatitis C Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Hepatitis C refers to an infectious disease caused by the hepatitis C virus that mainly affects the liver. It is transmitted through contact with blood from an infected person. The virus can result in both acute and chronic hepatitis, with symptoms ranging from mild to life-threatening, including liver cirrhosis and cancer. Some of the common indications associated with this condition are nausea, vomiting, fatigue, fever, muscle or joint pains, decreased appetite, abdominal pain, weight loss, jaundice, etc. Additionally, a few people may also experience dark urine and pale stools. The diagnosis of the ailment is based on the patient's medical history, a physical exam, and blood tests. The healthcare provider may perform a genetic work-up to monitor the type of hepatitis C virus (genotype). Various other investigations, such as enzyme-linked immunosorbent assay (ELISA), recombinant immunoblot assay, RNA polymerase chain reaction, etc., are utilized to detect antibodies against the virus. In addition to this, liver ultrasound and biopsy are required to examine liver damage and confirm a diagnosis.

The increasing incidences of injection drug use involving needle and syringe sharing, which can enhance the risk of virus transmission, are primarily driving the hepatitis C market. In addition to this, the rising prevalence of long-term kidney dialysis that can cause cross-contamination from surfaces and supplies due to failure to follow infection-control guidelines within the unit is also bolstering the market growth. Furthermore, the widespread adoption of antiviral drugs, including pegylated interferon and ribavirin, for treating the disease is acting as another significant growth-inducing factor. These medications can inhibit viral DNA synthesis and reduce the virus's ability to replicate. Additionally, several key players are making extensive investments in R&D activities to launch therapeutic vaccine technology to stimulate immunity among the population. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of combination therapy involving immune modulator drugs and nucleoside analogs, owing to its numerous advantages, such as slowing down or stopping viral reproduction and improving patient outcomes, is expected to drive the hepatitis C market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hepatitis C market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hepatitis C and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatitis C market in any manner.

Recent Developments:

• In June 2025, AbbVie announced that the U.S. FDA approved a label expansion for Mavyret (Glecaprevir/Pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis.
• In April 2025, pharmaand GmbH announced that the European Medicines Agency (EMA) had granted a variation to the Marketing Authorization for Pegasys (peginterferon alfa-2a), allowing Loba biotech GmbH, a wholly owned manufacturing subsidiary of pharma&, to be included as an approved site for the production of the active pharmaceutical ingredient, peginterferon alfa-2a. The authorization permits pharma& to begin Pegasys product replenishment across Europe, bolstering long-term supply chain resilience.

Key Highlights:

• Chronic hepatitis C is a leading cause of liver disease and cancer worldwide.
• More than 170 million individuals, or 2.2-3.0% of the global population, are chronically infected with hepatitis C virus.
• Approximately 85% of those infected with the hepatitis C virus have chronic infections that might potentially cause severe liver damage.
• The prevalence of hepatitis C virus antibodies (anti-HCV) in the general population of the United States is 1.8%.
• Every year, at least 400,000 individuals die as a result of hepatitis C virus infection causing liver failure and cancer.

Drugs:

Sovaldi (Sofosbuvir) is a direct-acting antiviral medication used to treat hepatitis C infection. Its mechanism of action involves inhibiting the HCV NS5B RNA-dependent RNA polymerase, a key enzyme required for viral replication. Specifically, sofosbuvir is a nucleotide prodrug that is converted to its active form, GS-461203, within the body. This active metabolite acts as a chain terminator when incorporated into the growing RNA strand by the NS5B polymerase, effectively halting viral replication.

Mavyret (Glecaprevir/Pibrentasvir) works by targeting the Hepatitis C virus in two ways to prevent it from multiplying: Glecaprevir inhibits a viral enzyme called NS3/4A protease, preventing the virus from creating necessary proteins, while Pibrentasvir inhibits another viral protein, NS5A, which is essential for viral replication and assembly. This dual action ensures a high genetic barrier to resistance, effectively suppressing HCV replication and leading to sustained viral responses.

TG-2349 is a HCV protease inhibitor. It works by targeting and inhibiting the NS3/4A serine protease, an enzyme essential for the replication of the Hepatitis C virus (HCV). By blocking this enzyme, TG-2349 prevents the virus from multiplying and spreading within the body.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hepatitis C market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hepatitis C market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hepatitis C marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hepatitis C market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the hepatitis C across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the hepatitis C across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of hepatitis C across the seven major markets?
• What is the number of prevalent cases (2019-2035) of hepatitis C by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of hepatitis C by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of hepatitis C by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with hepatitis C across the seven major markets?
• What is the size of the hepatitis C patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend hepatitis C of?
• What will be the growth rate of patients across the seven major markets?

Hepatitis C: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hepatitis C drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatitis C market?
• What are the key regulatory events related to the hepatitis C market?
• What is the structure of clinical trial landscape by status related to the hepatitis C market?
• What is the structure of clinical trial landscape by phase related to the hepatitis C market?
• What is the structure of clinical trial landscape by route of administration related to the hepatitis C market?